Prevalence of minority quasispecies of drug-resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002-2006

被引：0
作者：
Metzner, K. J. [1 ]
Rauch, P. [1 ]
von Wyl, V. [2 ]
Kuster, H. [2 ]
Stellbrink, H-J [3 ]
Boeni, J. [4 ]
Trkola, A. [2 ]
Weber, R. [2 ]
Guenthard, H. F. [2 ]
机构：
[1] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-8520 Erlangen, Germany
[2] Univ Zurich Hosp, Hosp Epidemiol, Div Infect Dis, Zurich, Switzerland
[3] Univ Hamburg Hosp, Inst Infect Med, Dept Med, Hamburg, Germany
[4] Univ Zurich, Swiss Natl Ref Ctr Retrovirus, CH-8006 Zurich, Switzerland
来源：
ANTIVIRAL THERAPY | 2007年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [41] Aptamers that recognize drug-resistant HIV-1 reverse transcriptase
    Li, Na
    Wang, Yuxuan
    Pothukuchy, Arti
    Syrett, Angel
    Husain, Naeem
    Gopalakrisha, Siddharth
    Kosaraju, Pradeepa
    Ellington, Andrew D.
    NUCLEIC ACIDS RESEARCH, 2008, 36 (21) : 6739 - 6751
  • [42] Drug-resistant HIV-1 in Cuban Children and their Seropositive Mothers
    Perez, Lissette
    Correa, Consuelo
    Aleman, Joan
    Gonzalez, Ida
    Perez, Jorge
    Martinez, Pedro A.
    Alvarez, Alina
    Soto, Yudiro
    Kouri, Vivian
    MEDICC REVIEW, 2011, 13 (02) : 24 - 31
  • [43] Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    Lazzarin, A
    Clotet, B
    Cooper, D
    Reynes, J
    Arasteh, K
    Nelson, M
    Katlama, C
    Stellbrink, H
    Delfraissy, J
    Lange, J
    Huson, L
    DeMasi, R
    Wat, C
    Delehanty, J
    Drobnes, C
    Salgo, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) : 2186 - 2195
  • [44] Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
    Frenkel, LM
    Mullins, JI
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) : 520 - 522
  • [45] Investigation of HIV-1 evolution following early therapy in patients with primary HIV-1 infection
    Huckett, L
    Devereux, H
    Loveday, C
    Kinloch, S
    Janossy, G
    AIDS, 1998, 12 : S22 - S22
  • [46] When Do Minority Drug-Resistant HIV-1 Variants Have a Major Clinical Impact?
    Heneine, Walid
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (05) : 647 - 649
  • [47] Substrate envelope based design of new HIV-1 protease inhibitors active against drug-resistant HIV-1
    Ali, Akbar
    Reddy, G. S. Kiran Kumar
    Nalam, Madhavi N. L.
    Anjum, Saima G.
    Cao, Hong
    Altman, Michael D.
    Tidor, Bruce
    Rana, Tariq M.
    Schiffer, Celia A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [48] Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV
    Quan, Yudong
    Xu, Hongtao
    Wainberg, Mark A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) : 21 - 27
  • [49] Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
    Ghosh, Arun K.
    Dawson, Zachary L.
    Mitsuya, Hiroaki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (24) : 7576 - 7580
  • [50] HIV-1 vif-derived peptide inhibits drug-resistant HIV proteases
    Blumenzweig, I
    Baraz, L
    Friedler, A
    Danielson, UH
    Gilon, C
    Steinitz, M
    Kotler, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 292 (04) : 832 - 840
12345